Supplemental table of contents

Supplemental figure 1. Genotyping of TIGIT-KO mice.

Supplemental figure 2. Gating strategy to assess TIGIT expression in Kidney and spleen.

Supplemental figure 3. Intracellular cytokine analysis of TIGIT+ and TIGIT- subsets of CD8 and DN T cells.

Supplemental figure 4. Analysis of memory phenotype in TIGIT+ and TIGIT- subsets of CD4+, CD8+ and DN kidney T cells.

Supplemental figure 5. TIGIT assessment in splenic Tregs at baseline and post-IR.

Supplemental figure 6. Intracellular cytokine analysis of CD4 and CD8 T cells from WT and TIGIT-KO kidneys at baseline.

Supplemental figure 7. scRNA-Seq analysis of flow sorted kidney CD45+ cells from WT and TIGIT-KO kidney at baseline and 24h post-IR injury.

Supplemental table 1: Primer sequences for CMV *Cre* and internal positive control used for genotyping TIGIT-KO mice.

Supplemental table 2: PCR conditions for CMV Cre detection.

Supplemental table 3: List of differentially expressed genes identified in bulk RNA-Seq analysis of flow-sorted CD4+ T cells from control and 24h post-IR kidneys of WT mice. (Excel File).

Supplemental table 4: KPMP scRNA-Seq data output result showing *TIGIT* expression by human kidney T cell subsets.

Supplemental figure legends

Supplemental Figure 1. Genotyping of TIGIT-KO mice. TIGIT-KO mice genotyping using CMV *Cre* detection using PCR primer and conditions provided in supplemental table 1 and 2 respectively. Lane 1 showing 100bp DNA ladder. TIGIT-KO mice in lane 2 showing 650bp PCR band, which is absent in WT mice in lane 3. Lanes 2 and 3 showing, 324bp internal positive control band in both TIGIT-KO and WT mice.

Supplemental Figure 2. Gating strategy to assess TIGIT expression in Kidney and

spleen. (A). Gating strategy used to define different kidney T cell populations and TIGIT+ and TIGIT- populations. (B) TIGIT expression in splenic T cells. Percentage of TIGIT expressing CD4+, CD8+ and DN T cells in spleen from control, sham, and post-IR (24h) mice. Data between groups was analyzed with unpaired non-parametric Mann-Whitney test. Graphs representing median (IQR) values.

Supplemental Figure 3. Intracellular cytokine analysis of TIGIT+ and TIGIT- subsets of CD8 and DN T cells. (A, B and C, D) Representative histograms and corresponding graphs showing percentage and MFI of proinflammatory cytokines IFN γ and TNF α in TIGIT+ and TIGIT- CD8+ T cells in control (baseline) and 24h after IR injury. (E, F and G, H) Representative histograms and corresponding graphs showing percentage and MFI of proinflammatory cytokines IFN γ and TNF α in TIGIT+ and TIGIT- DN T cells in control (baseline) and 24h after IR injury. Data between groups was analyzed with unpaired nonparametric Mann-Whitney test. Graphs representing median (IQR) values. * = p≤0.05, ** = p≤0.01. Supplemental Figure 4. Analysis of memory phenotype in TIGIT+ and TIGITsubsets of CD4+, CD8+ and DN kidney T cells. (A) Representative flow dot plots showing gating strategy used to define naïve, EM and CM subsets of TIGIT+ and TIGIT-T cells. (B) MFI of CD62L and CD44 expression in TIGIT+ and TIGIT- kidney CD4+ T cells at baseline and (C) after IR injury. (D, E and F, G) Percentage of naïve, EM and CM cells among TIGIT+ and TIGIT- CD8+ and DN T cells at baseline and 24h after IR injury. (H, I and J, K) MFI of CD62L and CD44 expression in TIGIT+ and TIGIT- CD8+ and DN T cells, at baseline and 24h after IR injury. Data between groups was analyzed with unpaired non-parametric Mann-Whitney test. Graphs representing median (IQR) values. * = $p \le 0.05$, ** = $p \le 0.01$, *** = $p \le 0.001$.

Supplemental Figure 5. TIGIT assessment in splenic Tregs at baseline and post-IR.

(A) Percentage of TIGIT+ and TIGIT- splenic Tregs among CD4+ T cells at baseline. (B) Percentage of TIGIT+ splenic Tregs at baseline (control) and 24h after kidney IR injury. Data between groups was analyzed with unpaired non-parametric Mann-Whitney test. Graphs representing median (IQR) values. ** = $p \le 0.01$

Supplemental Figure 6. Intracellular cytokine analysis of CD4 and CD8 T cells from WT and TIGIT-KO kidneys at baseline. (A, B and C, D) Percentage of IFN γ - and TNF α expressing CD4 and CD8 T cells from WT and TIGIT-KO kidneys at baseline. Data
between groups was analyzed with unpaired non-parametric Mann-Whitney test. Graphs
representing median (IQR) values. ** = p≤0.01

Supplemental Figure 7. scRNA-Seq analysis of flow sorted kidney CD45+ cells from
WT and TIGIT-KO kidney at baseline and 24h post-IR injury. (A) Violin plot showing
absence of *Tigit* expression in immune cells from TIGIT-KO mice compare to WT mice.
B) Violin plot showing increased *Tigit* expression in post-IR T cells compared to baseline
T cells in WT mice kidneys. (C) Violin plot representing *Tigit* expression in different T cell
subsets at baseline.

Supplemental Figure 1







Supplemental Figure 3



Supplemental Figure 4



Baseline



Baseline









Supplemental figure 6





Supplemental Table 1

	CMV Cre (NJ-Seq-7) forward primer	5'-GACGGTGTCCTCTCCATCTC -3'				
	CMV Cre (NJ-Seq-20) reverse primer	5'-GGAAGGGGAAGAGAGGACAA -3'				
	Internal positive control forward primer	5'-CTAGGCCACAGAATTGAAAGATCT-3'				
	Internal positive control reverse primer	5'-GTAGGTGGAAATTCTAGCATCATCC-3'				
Supplemental Table 1. Primer sequences used for CMV Cre detection in TIGIT KO mice and						

internal positive control to confirm successful PCR

Supplemental Table 2

Step	Temperature	time	cycles
1	94°C	3 min	
2	94°C	30 sec	
3	61°C	45 sec	35 cvcles
4	72°C	1 min	Cycles
5	72°C	5 min	
6	4°C	hold	

Supplemental Table 2. PCR conditions for CMV Cre detection

Supplemental Table 4

TIGIT Expression Comparison across Clusters in AKI

NS = Not Significant

				CLUSTER VS ALL OTHERS			
ABBR	CLUSTER (predicted state)	# CELLS IN CLUSTER	MEAN EXPRESSION ()	% CELLS EXPRESSING	FOLD CHANGE 3	P VALUE 🕄	ADJ P VALUE 🚯
T-REG	Regulatory T Cell	150	7.10	62.0	2.81	2.17e-205	6.60e-201
NKT	Natural Killer T Cell	889	2.66	27.9	1.71	9.43e-107	2.87e-102
T-CYT	Cytotoxic T Cell	479	1.85	23.6	1.30	1.69e-69	5.14e-65
NK1	Natural Killer Cell Type 1	426	2.17	23.7	1.46	5.97e-59	1.82e-54
cycT	T Cell (cycling ²)	153	1.31	20.9	0.972	2.29e-35	6.96e-31
NK2	Natural Killer Cell Type 2	93	1.12	14.0	0.851	1.13e-9	0.0000344
EC-AEA	Afferent / Efferent Arteriole Endothelial Cell	516	0	NS	NS	NS	NS

✓....

Supplemental Table 4. KPMP scRNA-Seq data output result showing *TIGIT* expression by different T cells subsets compared to all other cell type clusters in AKI patients.